• Publications
  • Influence
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
Clinicians can use these nomograms when counseling individual patients regarding the probability of their tumor being a specific pathological stage to enable patients and physicians to make more informed treatment decisions based on the probabilities of a pathological stage, as well as risk tolerance and the values they place on various potential outcomes. Expand
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
The influence of patient age and prostatic size on the serum PSA concentration was assessed in order to use PSA more appropriately to detect clinically significant prostate cancer at an early, potentially curable stage. Expand
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
It is unlikely that PSA by itself will become an effective screening tool for the early diagnosis of prostate cancer, but if combined with digital rectal examination and/or transrectal ultrasound it may become a vital part of any early detection program. Expand
The prevalence of prostatism: a population-based survey of urinary symptoms.
The specific urinary symptoms of nocturia, weak stream, restarting, urgency and sensation of incomplete emptying are strongly age-related and, therefore, may be predictive of a prostatic disease process. Expand
Prostate specific antigen: a decade of discovery--what we have learned and where we are going.
Although controversial, age specific PSA reference ranges can improve the sensitivity for prostate cancer detection in young men and the specificity in older men and further clinical trials are needed to determine its clinical usefulness. Expand
The management of renal angiomyolipoma.
Revue des cas de la litterature mondiale et de 13 cas personnels. Un schema therapeutique systematique est propose base a la fois sur la taille de la tumeur et les symptomes
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.
Patients undergoing radical prostatectomy for clinically localized prostate cancer were usually healthy and, thus, had low co-morbidity and survival rates at 10 and 15 years compare favorably with those of an age-matched control group. Expand
The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
For patients with newly diagnosed, untreated prostate cancer, a serum PSA concentration of 10.0 micrograms/L or less, and no skeletal symptoms, a staging radionuclide bone scan does not appear to be necessary. Expand
Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies.
The results indicate that the presence of high grade prostatic intraepithelial neoplasia on needle biopsy is strongly predictive of carcinoma. Expand
Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.
The results support the premise that the recent increase in prostate cancer is due in part to the increased utilization of serum PSA testing and suggest that early detection efforts may be effective in identifying more early stage (smaller) cancers. Expand